C4 Therapeutics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its first-quarter results, which were ahead...
US stocks mixed, Nasdaq up 200 points. Dow down 0.43%, Nasdaq up 0.79%, S&P 500 up 0.27%. Communication services up 1.6%, utilities down 1.4%. Alibaba shares up 6% after reporting mixed Q4 results. Velo3D up 47%, Wix.com down 30%, National Vision down 25%.
Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius Group (NBIS) up 16.6%, Sellas Life Sciences (SLS) up 15.5%, Eos Energy (EOSE) up 14.6%, Nextpower (NXT) up 14.4%.
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Protein degraded. Disease targeted. Lives transformed. May 2026 Advancing Differentiated TPD Medicines and...
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 45.95 percent increase over losses of $(0.37) per share from
Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with...
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Roche Holding (SWX:ROG) shares are in focus after C4 Therapeutics announced a new collaboration to develop degrader antibody conjugates for oncology, combining targeted protein degradation with antibody drug conjugation. See our latest analysis for Roche Holding. Roche Holding's share price has softened recently, with a 1 month share price return of 10.47% and a 7 day share price return of 3.04%. However, the 1 year total shareholder return stands at 10.30%, which hints that long term...
Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.
The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation. Opportunities lie in emerging therapies from key players and unmet needs for improved treatment options.Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offe
Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates for cancer treatment. The partnership combines targeted protein degradation with antibody drug conjugation to explore new oncology drug modalities. Roche receives exclusive rights to selected oncology targets, with the agreement including milestone payments and royalties. Roche Holding, trading at around CHF315.6, has a strong oncology franchise and is now adding a fresh...
Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates for cancer treatment. The partnership combines targeted protein degradation with antibody drug conjugation to explore new oncology drug modalities. Roche receives exclusive rights to selected oncology targets, with the agreement including milestone payments and royalties. Roche Holding, trading at around CHF315.6, has a strong oncology franchise and is now adding a fresh...
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 3.04M | $7.98M | 0.01% | Added+101.1% | 2026-03-31 |
| RenTech | quant | 2.46M | $6.47M | 0.01% | Added+53.6% | 2026-03-31 |
| DEShaw | quant | 1.06M | $2.79M | 0.00% | Added+1905.2% | 2026-03-31 |
| StateStreet | passive | 383.0K | $1.01M | 0.00% | Added+11.7% | 2026-03-31 |
| FidelityFMR | fundamental | 272.4K | $716.33K | 0.00% | Added+7.1% | 2026-03-31 |
| Citadel | multi-strat | 169.1K | $444.72K | 0.00% | Trimmed-98.2% | 2026-03-31 |
| TRowePrice | fundamental | 71.5K | $189 | 0.00% | Added+477.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.24 | — | — |
| 2026-05-12 | -0.26 | -0.20 | +23.08% |
| 2026-02-26 | -0.39 | -0.18 | +54.24% |
| 2025-11-06 | -0.41 | -0.44 | -7.68% |
| 2025-08-07 | -0.38 | -0.37 | +3.27% |
| 2025-05-07 | -0.43 | -0.37 | +13.56% |
| 2025-02-27 | -0.45 | -0.49 | -8.80% |
| 2024-10-31 | -0.33 | -0.35 | -7.14% |
| 2024-08-01 | -0.18 | -0.26 | -44.44% |
| 2024-05-08 | -0.26 | -0.38 | -46.95% |
| 2024-02-22 | -0.69 | -0.68 | +1.41% |
| 2023-11-01 | -0.65 | -0.54 | +17.88% |
| 2023-08-08 | -0.69 | -0.73 | -5.56% |
| 2023-05-04 | -0.75 | -0.71 | +5.08% |
| 2023-02-23 | -0.59 | -0.76 | -29.90% |
| 2022-11-03 | -0.61 | -0.65 | -7.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CCCC | +49.66% | +48.14% | +128.80% | +249.60% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +46.69% | +52.77% | +132.24% | +236.91% |